Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries ... a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia. The world's largest generic drugmaker ...

SELARSDI is the second biosimilar to be ... to severely active Crohn’s disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech ...

Teva reported growth for the second year in a row ... The Motley Fool has a disclosure policy. Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript Teva Pharmaceutical Industries ...

positive Phase 2b results at the 20th Annual Congress of Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye ...

like its drug targeting ulcerative colitis and Crohn's disease. Though it looks promising, the company has its work cut out for it. Before you buy stock in Teva Pharmaceutical Industries ...

In October 2024, the U.S. Food and Drug Administration (FDA ... 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference ...

protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up ...